VRTX Operating cash flow
Operating cash flow at Vertex Pharmaceuticals rose to $3.6B in fiscal 2025, from −$493M in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 875320 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$3.6B
FY2024 −$493M
HIGH$4.1B FY2022
LOW−$493M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $3.6B | +$4.1B |
| FY2024 | −$493M | $-4.0B |
| FY2023 | $3.5B | $-593M |
| FY2022 | $4.1B | +$1.5B |
| FY2021 | $2.6B | — |
More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · VRTX company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.